MR imaging appearance of the uterus in postmenopausal women receiving tamoxifen therapy for breast cancer: Histopathologic correlation

Radiology

Volumn 200, Issue 1, 1996, Pages 105-110

  Ascher, Susan M ^a   Johnson, Jacqueline C ^b   Barnes, Willard A ^a   Bae, Charles J ^a   Patt, Richard H ^a   Zeman, Robert K ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Breast neoplasms, therapy; Gadolinium; Uterus, cysts; Uterus, endometrium; Uterus, MR

Indexed keywords

GADOLINIUM PENTETATE MEGLUMINE; TAMOXIFEN;

ADENOMYOSIS; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYST; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTMENOPAUSE; PRIORITY JOURNAL; UTERUS DISEASE; UTERUS MYOMA;

EID: 0029888914     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.200.1.8657895     Document Type: Article

References (28)

1. Nay field SG, Karp JE, Ford LG, et al. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 1991; 83: 1450-1459.
2. Neven P, De Muylder X, Van Belle Y, et al. Tamoxifen and the uterus and endometrium (abstr). Lancet 1989; 2:375.
3. De Muylder X, Neven P, De Somer M, et al. Endometrial lesions in patients undergoing tamoxifen therapy.Int J Gynecol Obstet 1991; 36:127-130.
4. Neven P, De Muylder X, Van Belle Y, et al. Hysteroscopic follow-up during tamoxifen treatment. Eur J Obstet Gynecol Reprod Biol 1990; 35:235-238.
5. Gal D, Kopel S, Bashevkin M, et al. Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer: preliminary report. Gynecol Oncol 1991; 42:120-123.
6. Fornander T, Rutquist LE, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989; 2:117-120.
7. Van Leeuwen FE, Benraadt J, Coegergh JWW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994; 343:448-452.
8. Hardell L. Pelvic irradiation and tamoxifen as risk factors for carcinoma of corpus uteri (letter). Lancet 1988; 2:1432.
9. Fisher B, Constantino JP, Rodmond CK, et al. Endometrial cancer in tamoxifentreated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86:527-537.
10. Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 1991; 83:1013-1017.
11. Uziely B, Lewin A, Brufman G, et al. The effect of tamoxifen on the endometrium. Breast Cancer Res Treat 1993; 26:101-105.
12. Sismondi P, Biglia N, Volpi E, et al. Tamoxifen and endometrial cancer. Ann NY Acad Sci 1994; 734:310-321.
13. Bissett D, Davis JA, George WD. Gynaecological monitoring during tamoxifen therapy. Lancet 1994; 344:1244.
14. Kedar RP, Bourne TH, Powles TJ, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994; 343:1318-1321.
15. Hulka CA, Hall CA. Endometrial abnormalities associated with tamoxifen therapy for breast cancer: sonographic and pathologic correlation. AJR 1993; 160:809-812.
16. Goldstein SR. Unusual ultrasonic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 1994; 170: 447-451.
17. Cohen I, Rosen DJD, Tepper R, et al. Ultrasonographic evaluation of the endometrium and correlation with endometrial sampling in postmenopausal patients treated with tamoxifen. J Ultrasound Med 1993; 5:275-280.
18. Lahti E, Blance G, Kauppila A, et al. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993; 81:660-664.
19. Hricak H, Hamm B, Semelka RC, et al. Carcinoma of the uterus: use of gadopentetate dimeglumine in MR imaging. Radiology 1991; 181:95-106.
20. Smith RC, Reinhold C, Lange RC, et al. Fast spin-echo MR imaging of the female pelvis. I. Use of a whole-volume coil. Radiology 1992; 184:665-669.
21. Hricak H, Finck S, Honda C, Goranson H. MR imaging in the evaluation of benign uterine masses: value of gadopentetate dimeglumine-enhanced T1-weighted images. AJR 1992, 158:1043-1050.
22. Ito K, Matsumoto I, Nakada T, et al. Assessing myometrial invasion by endometrial carcinoma with dynamic MRI. J Cornput Assist Tomogr 1994; 18:77-86.
23. Togashi K, Nishimura K, Itoh K, et al. Adenomyosis: diagnosis with MR imaging. Radiology 1988; 166:111-114.
24. Arnold LL, Ascher SM, Schruefer JJ, Simon JA. The nonsurgical diagnosis of adenomyosis. Obstet Gynecol 1995; 86:461-465.
25. Cohen I, Altaras MM, Shapira J, et al. Postmenopausal tamoxifen treatment and endometrial pathology: obstetrical and gynecological survey. Baltimore, Md: Williams & Wilkins, 1994; 4:823-829.
26. Cohen I, Beth Y, Tepper B, et al. Adenomyosis in postmenopausal breast cancer patients treated with tamoxifen: a new entity? Gynecol Oncol 1995; 58:86-91.
27. Compel C, Silverberg SG. The corpus uteri. In: Compel C, Silverberg SG, eds. Pathology in gynecology and obstetrics. Philadelphia, Pa: Lippincott, 1994; 163-283.
28. Ugwumadu AH, Bower D, Kin-Hoi P. Tamoxifen-induced adenomyosis and adenomatous polyp. Br J Obstet Cynecol 1993; 100:386-392.